a. Given that this is the second delay for Johnson & Johnson in these drug trials, what does this say about its management controls?
b. Of the four “areas of alleged deficiency,” which one represents the greatest management challenge to correct? Why?
c. What will be the consequences for these trials and for the organization if J&J fails to correct these errors?
d. If you were assigned to manage this project now, what would be your first step?